Pharmaceuticals

Economics and Australian Health Policy

Volumn , Issue , 2020, Pages 115-136

  Salkeld, Glenn ^a   Mitchell, Andrew ^c   Hill, Suzanne ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85096251966     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9781003115441-6     Document Type: Chapter

References (48)

1. Aristides, M. & Mitchell, A.S. (1994) ‘Applying the Australian Guidelines for the reimbursement of pharmaceuticals’, PharmacoEconomics 6: 196-201.
2. Australian Bureau of Statistics (ABS) (1996) National Health Survey, 1995: First Results. Catalogue no. 4392.0, ABS, Canberra.
3. Bureau of Industry Economics (BIE) (1991) The Pharmaceutical Industry: Impediments and Opportunities, Bureau of Industry Economics Program Evaluation Report 11, 1991.
4. Canadian Coordinating Office for Health Technology Assessment (1994) Guidelines for Economic Evaluation of Pharmaceuticals. CCOHTA, Ottawa.
5. Carmine, B. (1996) ‘Update and evaluation of Australian Guidelines: industry perspective’, Med Care 34, 12(supp): DS226-32.
6. Chalanson, G. (1997) ‘An industry’s perspective on the French system of taking into account of a pharmacoeconomic dossier for setting prices of pharmaceuticals’, 2nd Conference on the Scientific Basis of Health Services, Abstract SI5.03. Amsterdam, October.
7. Commonwealth of Australia (1987) Hansard. National Health Amendment Bill (no. 2). Second Reading Speech, Canberra.
8. Commonwealth of Australia (1990) Draft Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. AGPS, Canberra.
9. Commonwealth of Australia (1992) Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. AGPS, Canberra.
10. Commonwealth of Australia (1995) Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. AGPS, Canberra.
11. Commonwealth of Australia (1996a) Pharmaceutical Benefits Pricing Authority Annual Report for the year ended 30 June 1996. AGPS, Canberra.
12. Commonwealth of Australia (1996b) The pharmaceutical industry: Industry Commission Report, Vol. 2. AGPS, Canberra.
13. Commonwealth of Australia (1997a) Expenditure and prescriptions twelve months to 30 June 1997. CDHFS, Pharmaceutical Benefits Branch, Canberra.
14. Commonwealth of Australia (1997b) The Australian Pharmaceutical Benefits Scheme. CDHFS, Canberra.
15. Davis, G., Wanna, J., Warhurst, J. & Weller, P. (1993) Public Policy in Australia, 2nd edn. Allen & Unwin, Sydney.
16. Drummond, M.F. (1994) Value for Money Assessments in Australia and Beyond, Spectrum Health Care Delivery and Economics, Decisions Resource, Ma.
17. Duckett, S. (1997) ‘The policy change process’, in H. Gardner (ed.) Health Policy in Australia, Oxford University Press, Melbourne.
18. Elgar, E. (1992) ‘Policies and issues’, in R. Ballance, J. Pogany & H. Forstner (eds) The World’s Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy, United Nations Industrial Development Organisation, Geneva.
19. Food and Drug Administration (FDA) (1995) Principles for the Review of Pharmacoeconomic Promotion: Draft Guidelines, US Food and Drug Administration, Rockville, MD.
20. Freund, D.A. (1996) ‘Initial development of the Australian Guidelines’, Med Care 34, 12(supp): DS211-15.
21. Garattini, L., Grilli, R., Scopelliti, D. & Mantovani, L. (1995) ‘A proposal for Italian guidelines in pharmacoeconomics’, PharmacoEconomics 7: 1-6.
22. Genduso, L.A. & Kotsanos, K.G (1996) ‘Review of health economic Guidelines in the form of regulations, principles, policies, and positions’, Drug Information Journal 30: 1003-16.
23. George, B., Harris, A. & Mitchell, A. (in press) ‘Reimbursement decisions and the implied value of life: cost effectiveness analysis and decisions to reimburse pharmaceuticals in Australia 1993-1996', in Harris, A. (ed.) Proceedings of the Nineteenth Australian Conference of Health Economists, Australian Studies in Health Service Administration, University of New South Wales, Sydney.
24. Glasziou, P.P. & Mitchell, A.S. (1996) ‘Use of pharmacoeconomic data by regulatory authorities’, in B. Spilker (ed.) Quality of Life and Pharmacoeconomic in Clinical Trials, 2nd edn, Lippincott-Raven, Philadelphia, PA.
25. Gold, M.R., Siegel, J.E., Russell, L.B. et al. (1996) Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-effectiveness in Health and Medicine, Oxford University Press, New York.
26. Gorham, P. (1995) ‘Cost-effectiveness Guidelines: the experience of Australian manufacturers’, PharmacoEconomics 8: 369-73.
27. Grant, C. & Lapsley, H.M. (1996) The Australian Health Care System, 1995, Australian Studies in Health Service Administration, UNSW, Sydney.
28. Grobler, M.P., Macarounas, K., Pearce, GS. & Stafford, M. (1996) ‘Industry comment on the 1995 revised Australian pharmacoeconomic Guidelines’, PharmacoEconomics 9: 353-6.
29. Grund, J. (1996) ‘The societal value of pharmaceuticals: balancing industrial and health care policy’, PharmacoEconomics 10: 14-22.
30. Hall, R. (1989) ‘Drug regulation in Australia’, Med J Aust 151: 338-40.
31. Harvey, K. & Murray, M. (1995) ‘Medicinal drug policy’, in H. Gardner (ed.) The Politics of Health: The Australian Experience, 2nd edn, Churchill Livingstone, Melbourne.
32. Henry, D. (1992) ‘Economic analysis as an aid to subsidisation decisions’, PharmacoEconomics 1: 54-67.
33. Henry, D. (1997) ‘Prescribing costs: whose responsibility?', Australian Prescriber 20: 26-7.
34. Hill, S., Henry, D. & Smith, A. (1997) ‘Rising prescription drug costs: whose responsibility?', Med J Aust 167: 6-7.
35. Langley, P.C. (1996) ‘The November 1995 revised Australian Guidelines for the economic evaluation of pharmaceuticals’, PharmacoEconomics 9: 341-52.
36. Langley, P.C. & Sullivan, S.D. (1996) ‘Pharmacoeconomic evaluations: Guidelines for drug purchasers’, J Managed Care Pharm 2: 671-7'.
37. Lomas, J. (1996) The Sound of One Hand Clapping, Department of Public Health and Community Medicine, University of Sydney, Sydney.
38. Marley, J. (1996) ‘Cost-effectiveness: the need to know’, AustralianPrescriber 19: 58-9.
39. Milio, N. (1988) Making Policy: A Mosaic of Australian Community Health Policy Development, Commonwealth Department of Community Services and Health, Canberra.
40. Mitchell, A.S. (1996a) ‘Current experience in Australia’, Drug Information Journal 30: 495-502.
41. Mitchell, A.S. (1996b) ‘Update and evaluation of Australian Guidelines: government perspective’, Med Care 34, 12(supp): DS216-25.
42. Mitchell, A.S. & Menon, D. (1996) ‘Guidelines for pharmacoeconomics: state of the art’, in A. Szczepura & J. Kankaanpaa (eds) Assessment of Health Care Technologies: Case Studies, Key Concepts and Strategic Issues, John Wiley & Sons, New York
43. Neumann, P.J. & Johannesson, M. (1994) ‘Commentary. From principle to public policy: using cost-effectiveness analysis’, Health Affairs Summer: 206-14.
44. Neumann, P.J., Zinner, D.E. & Paltiel, D. (1996) ‘The FDA and regulation of cost-effectiveness claims’, Health Affairs 15: 54-71.
45. Ontario Ministry of Health (1994) Ontario Guidelines for Economic Analysis of Pharmaceutical Products, Queen’s Printer for Ontario, Toronto.
46. Agence du Médicament (1995) Acceptabilité des Études Médico-Économiques: Contenu et Presentation, Agence du Médicament, Saint-Denis.
47. Salkeld, G., Davey, P.D. & Arnolda, G. (1995) ‘A critical review of health-related economic evaluations in Australia: implications for health policy’, Health Policy 31:111-25.
48. Shiell, A. & Salkeld, G. (1997) ‘The economic aspects of interferon’, in R. Stuart-Harris & R. Penny (eds) Clinical Applications of the Interferons, Chapman & Hall Medical, London.